Alterity Therapeutics Files 6-K Report

Ticker: ATHE · Form: 6-K · Filed: Apr 1, 2026 · CIK: 0001131343

Sentiment: neutral

Topics: foreign-issuer, report, presentation

TL;DR

Alterity Therapeutics filed a 6-K, looks like a presentation deck was attached.

AI Summary

Alterity Therapeutics Ltd. filed a Form 6-K on April 1, 2026, reporting for the period ending April 30, 2026. The filing includes various documents, primarily image files (slides), suggesting a presentation or update was provided. No specific financial figures or material events are detailed in the provided text.

Why It Matters

This filing indicates Alterity Therapeutics is providing an update, likely to investors or stakeholders, though the specific content requires examining the linked exhibits.

Risk Assessment

Risk Level: low — The filing is a routine report of foreign issuer and does not contain specific financial disclosures or material events that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The Form 6-K is a report of a foreign issuer, filed by Alterity Therapeutics Ltd. on April 1, 2026, for the period ending April 30, 2026.

What type of documents are included in this filing?

The filing includes a Form 6-K document and numerous image files (slides), indicated by filenames like 'slide01.jpg' through 'slide39.jpg'.

When was this filing accepted by the SEC?

This filing was accepted by the SEC on April 1, 2026, at 06:10:30.

What is the mailing address listed for Alterity Therapeutics Ltd.?

The mailing address listed is LEVEL 3, 460 BOURKE STREET, MELBOURNE, Australia.

Does the provided text detail any specific financial results or material events?

No, the provided text of the filing summary does not detail specific financial results or material events; it primarily lists the documents included in the submission.

Filing Stats: 183 words · 1 min read · ~1 pages · Grade level 12.7 · Accepted 2026-04-01 06:10:30

Filing Documents

From the Filing

athe20260401_6k.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Corporate Presentation April 2026 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Julian Babarczy Julian Babarczy Chairman Date: April 1, 2026 2

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing